Short answer
Moderna (MRNA) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $1.0B (down 45.4% year over year) with net income of −$200M.
Q3 2025 key financials · XBRL
- Revenue
- $1.0B
- −45.4% YoY · +615.5% QoQ
- Net income
- −$200M
- −1638.5% YoY · +75.8% QoQ
- Operating margin
- -25.6%
- EPS (diluted)
- −$0.51
- −1375.0% YoY · +75.9% QoQ
Source: XBRL data from the Moderna (MRNA) Q3 2025 10-Q on SEC EDGAR. USD.
Moderna Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Section 'mda' was empty or not found.
Risk Factors
- No material changes to risk factors from 2024 Form 10-K
- Continued dependency on successful development and commercialization of vaccine candidates
- Regulatory risks related to approvals, inspections, and compliance with FDA and global authorities
- Market risk from competitive vaccine landscape and evolving COVID-19 variants impacting sales
- Financial risk from reliance on milestone payments and potential fluctuations in government contract revenues
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Moderna quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.